GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
Betsy Goodfellow | March 18, 2024 | News story | Research and Development | GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) in combinations for the treatment of adult patients with primary advanced or recurrent endometrial cancer.
The results demonstrated a statistically significant and clinically meaningful overall survival (OS) in part 1 and progression free survival (PFS) in part 2, and were presented at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer, taking place from 16-18 March.
Part 1 investigated Jemperli plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo. Part 2 then assessed Jemperli plus standard-of-care chemotherapy followed by Jemperli plus niraparib as a maintenance therapy, compared to chemotherapy plus placebo followed by placebo.
Both parts of the trial demonstrated safety profiles for all drugs that were consistent with the known safety profiles of the medications when used as individual drugs.
Hesham Abdullah, senior vice president and global head Oncology R&D at GSK, commented: “The positive data presented today further show how dostarlimab-based regimens could benefit a broader set of patients with endometrial cancer. The results we’ve seen to date comprise the growing body of evidence supporting the role of dostarlimab as the backbone of our immuno-oncology development programme. Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options.”
Betsy Goodfellow
Related Content
GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
